MOTS-c dosing research protocols — reconstitution, the short half-life, handling

“What is the MOTS-c dose?” is one of the most-searched questions about the mitochondrial-derived peptide — and the honest answer begins by refusing the premise. There is no validated human dose of MOTS-c for any purpose, because MOTS-c is not an approved medicine in any major jurisdiction and has never been through the dose-finding programme that would establish one. What does exist is a published research record — almost entirely animal work — describing the amounts those studies administered. This spoke reports those figures descriptively, explains why a relatively large 16-mer with a short plasma half-life is a genuinely unusual administration problem, shows the reconstitution math, and is explicit throughout that this is a research reference, not a protocol to follow. The MOTS-c parent synopsis covers what the molecule is.

Why there is no validated human dose

The first thing to settle, before any number appears, is what kind of object a “MOTS-c dose” is. It is not an approved dosing instruction, because MOTS-c is not an approved medicine anywhere in the major regulatory world — there is no regulator-reviewed label, no marketed strength, and no dose-ranging programme that ran to registration. MOTS-c is a comparatively recent discovery: it was first reported in 2015 as a mitochondrial-derived peptide encoded within the 12S ribosomal RNA gene [1], and the bulk of the dosing record since then is animal work, not human interventional trials.

That matters because the figures circulating on forums and vendor pages are extrapolations. They take the amounts administered in rodent experiments — expressed per kilogram of body mass, as animal pharmacology always is — and present them as though they were human protocols. They are not. Human interventional dosing of exogenous MOTS-c is early, and the observational human data concerns endogenousplasma concentrations, not administered doses. So nothing below is a recommendation, and there is no validated human dose of MOTS-c for any unapproved use. Read every figure that follows as “what these studies administered”, never as “what to take”.

There is no validated human dose of MOTS-c. The numbers that circulate are research-reference figures — what specific animal studies administered to observe an effect — not a protocol for any person to follow.

The PK nuance — short in plasma, longer in tissue

The reason MOTS-c is an unusually interesting administration problem — and the reason its “dosing” question cannot simply be lifted from a smaller peptide — is its pharmacokinetic profile. MOTS-c is a relatively large peptide at 16 residues and approximately 2,174 Da, and like most peptides of that size it is cleared from circulation quickly: the plasma half-life is short, on the order of 1-2 hours. If circulating concentration were the only thing that mattered, that short window would make the molecule difficult to work with.

But circulating concentration is not the whole story. The pharmacologically relevant parameter for MOTS-c is tissue uptake — the peptide is taken up into and retained by its target tissues, principally skeletal muscle and liver, for longer than its brief plasma presence would suggest. MOTS-c acts inside those tissues through AMPK metabolic signalling, so the question that shapes its administration research is not “how do we keep plasma levels high” but “how do we deliver enough peptide to the relevant tissue compartment, given that it leaves the bloodstream fast but lingers where it acts”.

Short in plasma, longer in tissue. That split — a roughly 1-2 hour circulating half-life against longer skeletal-muscle and liver residence — is the single fact that shapes how MOTS-c administration is studied.

Within that frame, the published animal protocols are straightforward to describe. The discovery-era work and the studies that followed administered MOTS-c by intraperitoneal or subcutaneous injection at roughly 0.1-1.0 mg per kilogram of body mass per day, scaled to the research question [1]. Those are animal pharmacology figures — the per-kilogram dimension does not translate directly into a human amount, and no validated conversion exists. Study durations ranged from acute single-dose pharmacokinetic experiments through chronic 4-12 week courses; the longer courses are the ones used for adaptation endpoints such as exercise capacity, where the meaningful changes unfold over weeks rather than hours [2]. Read each of those numbers as what the experiment administered, not as a regimen anyone should reproduce.

Reconstitution & the concentration math

Chemically, reconstituting MOTS-c is routine peptide handling. It is supplied as a lyophilised powder and is water-soluble, so it dissolves readily in the standard diluent. The mechanics, as a laboratory-handling procedure, are the same as for any research peptide: introduce bacteriostatic water — sterile water with roughly 0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake: shaking shears and can denature the peptide. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide. The math below shows how a chosen mass maps onto syringe units — it is laboratory handling arithmetic, not a use instruction.

Storage & handling

Storage discipline for MOTS-c follows the standard lyophilised-peptide pattern. As a freeze-dried powder it is most stable at -20°C, protected from light; once reconstituted, the solution is generally kept refrigerated at 2-8°C with a typical 28-day re-entry windowstated on the vendor’s documentation. The benzyl alcohol preservative in bacteriostatic water is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation.

The handling subtlety worth flagging is quality verification. Because the dose “figures” that circulate are only meaningful if the mass in the vial is what the label claims, the certificate of analysis is doing real work. A research-grade material should arrive with a third-party RP-HPLC purity assay of at least 98% peak area and mass-spectrometry confirmation of the parent ion at approximately 2,174 Da, consistent with the 16-residue MOTS-c sequence. Without that documentation the “dose” on the label is only as trustworthy as the mass actually present — and for a 16-mer of this size, manufacturing variance is real.

Cycles and “protocols” — convention vs evidence

The multi-week schedules that circulate — a run of consecutive days, a break, a repeat — are presented online as though they were established protocols. They are not derived from any published human dose-response work. They are convention: patterns that propagate through forums and vendor pages, often loosely echoing the chronic 4-12 week course structure of the animal studies without any of the dose-finding rigour that would justify a specific human schedule.

The honest distinction is between what the literature describes and what it validates. The published record describes MOTS-c administered in courses in animal models — the discovery work characterising route and skeletal-muscle target [1], and later work positioning MOTS-c as an exercise-induced regulator of AMPK metabolic signalling and exercise capacity [2]. None of that amounts to a controlled human trial validating any particular cycle length, per-kilogram amount, or dosing frequency for general use. So a “cycle” is a convention to recognise when reading the literature — not a dose-response-derived protocol, and not a recommendation made here.

A circulating “MOTS-c cycle” is convention, not evidence. No controlled human trial has validated a particular dose, frequency, or course length — the published courses describe animal experiments, not a protocol for people.

Related reading in the MOTS-c cluster

For what MOTS-c is, its mitochondrial-encoded-peptide context, and where its research record stands, start with the MOTS-c parent synopsis. For the molecular biology, see MOTS-c mechanism research; for the metabolic and exercise-physiology literature, see MOTS-c exercise and metabolic research. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: MOTS-c 10 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Lee et al. — Cell Metab 2015. The discovery report for MOTS-c as a mitochondrial-derived peptide encoded in the 12S rRNA gene; characterises route of administration and the skeletal-muscle target relevant to the AMPK metabolic-signalling axis. Cited here for mechanism and route context.
• [2] Reynolds et al. — Nat Commun 2021. Positions MOTS-c as an exercise-induced regulator, providing administration-research context for the chronic-course endpoints such as exercise capacity.

Last reviewed 12 June 2026. MOTS-c is not an approved medicine in any major jurisdiction; this article is research education and not medical advice, and nothing here describes a dose for any person to take. Wellness Labs supplies MOTS-c as research-grade lyophilised powder for non-clinical investigation — research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.